Summit Therapeutics (SMMT) Research & Development (2016 - 2025)
Historic Research & Development for Summit Therapeutics (SMMT) over the last 9 years, with Q3 2025 value amounting to $131.1 million.
- Summit Therapeutics' Research & Development rose 24751.35% to $131.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $441.8 million, marking a year-over-year increase of 25566.18%. This contributed to the annual value of $150.8 million for FY2024, which is 15353.03% up from last year.
- As of Q3 2025, Summit Therapeutics' Research & Development stood at $131.1 million, which was up 24751.35% from $208.0 million recorded in Q2 2025.
- In the past 5 years, Summit Therapeutics' Research & Development registered a high of $208.0 million during Q2 2025, and its lowest value of $5.4 million during Q4 2022.
- Moreover, its 4-year median value for Research & Development was $30.9 million (2024), whereas its average is $54.9 million.
- Its Research & Development has fluctuated over the past 5 years, first tumbled by 1012.38% in 2023, then soared by 57543.67% in 2025.
- Over the past 4 years, Summit Therapeutics' Research & Development (Quarter) stood at $5.4 million in 2022, then surged by 360.71% to $24.8 million in 2023, then soared by 107.07% to $51.4 million in 2024, then skyrocketed by 155.14% to $131.1 million in 2025.
- Its Research & Development stands at $131.1 million for Q3 2025, versus $208.0 million for Q2 2025 and $51.3 million for Q1 2025.